ResMed tops estimates after posting 11% rise in Q2 revenue
Make us a preferred source
Make us a preferred source on Google
The news: Sleep apnea device maker ResMed has reported an 11% jump in second-quarter revenue to USD1.4 billion ($2 billion) following strong demand for its sleep and respiratory care products.
The numbers: ResMed's gross margin was up 320 basis points to 61.8%. Income from operations increased 18% to USD491.7 million, while diluted earnings per share lifted 15% to USD2.68.
The context: RBC Capital Markets analyst Craig Wong-Pan said the result was a "slight beat" to consensus expectations across almost all metrics.
He noted mask sales in the Americas region outstripped estimates by 4%, and rest of world mask sales were 6% above expectations.
What they said: "As we move into the second half of fiscal year 2026, we will continue to invest in innovation to scale our digital health capabilities and expand global access to life-saving care, while delivering sustainable, profitable growth," said Resmed chairman and CEO Mick Farrell.
The source: ASX
